Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly-Reference-Cited by-同舟云学术

Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly

Published:2008-12-17 Issue:3 Volume:12 Page:196-199
ISSN:1386-341X
Container-title:Pituitary
language:en
Short-container-title:Pituitary

Author:

Bianchi Antonio,Mazziotti Gherardo,Tilaro Laura,Cimino Vincenzo,Veltri Flora,Gaetani Eleonora,Pecorini Giovanni,Pontecorvi Alfredo,Giustina Andrea,De Marinis Laura

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s11102-008-0157-8.pdf

Reference20 articles.

1. Kopchick JJ, Parkinson C, Stevens EC et al (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623–646. doi: 10.1210/er.2001-0022

2. Melmed S, Casanueva F, Cavagnini F et al (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737–740. doi: 10.1530/eje.1.02036

3. Muller AF, Kopchick JJ, Flyvbjerg A et al (2004) Clinical review 166: growth hormone receptor antagonists. J Clin Endocrinol Metab 89:1503–1511. doi: 10.1210/jc.2002-022049

4. Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N Engl J Med 342:1171–1177. doi: 10.1056/NEJM200004203421604

5. van der Lely AJ, Hutson RK, Trainer PJ et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754–1759. doi: 10.1016/S0140-6736(01)06844-1

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus on criteria for acromegaly diagnosis and remission;Pituitary;2023-11-03

2. The Exon 3-Deleted Growth Hormone Receptor (d3GHR) Polymorphism—A Favorable Backdoor Mechanism for the GHR Function;International Journal of Molecular Sciences;2023-09-10

3. Second line treatment of acromegaly: Pasireotide or Pegvisomant?;Best Practice & Research Clinical Endocrinology & Metabolism;2022-12

4. Pegvisomant: Lessons Learned After 20 Years and Practical Recommendations of Its Use for the Treatment of Acromegaly;Acromegaly;2022

5. From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?;Endocrine, Metabolic & Immune Disorders - Drug Targets;2021-10